| BCRX Stock | | | USD 7.50 0.01 0.13% |
SVP
Dr. Yarlagadda S. Babu, Ph.D., serves as a Senior Vice President Drug Discovery of the company. Dr. Babu joined BioCryst in 1988 and was BioCrysts first fulltime employee. Dr. Babu has served as the Companys Vice President Drug Discovery since 1992. In October of 2013, Dr. Babus title was changed to Senior Vice President of Drug Discovery. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham since 2013.
| Age | 71 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 4505 Emperor Boulevard, Durham, NC, United States, 27703 |
| Phone | 919 859 1302 |
| Web | https://www.biocryst.com |
Babu obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, U.K. before joining UAB. He has over 70 publications in peerreviewed journals, and a number of issued and pending patents to his credit.
BioCryst Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.0425) % which means that it has lost $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Equity is likely to rise to 0.52 in 2024, whereas
Return On Tangible Assets are likely to drop
(0.46) in 2024. At this time, BioCryst Pharmaceuticals'
Total Assets are fairly stable compared to the past year.
Non Current Assets Total is likely to rise to about 24.6
M in 2024, whereas
Non Currrent Assets Other are likely to drop slightly above 76
K in 2024.
BioCryst Pharmaceuticals currently holds 848.71
M in liabilities with Debt to Equity
(D/E) ratio of 2.4, implying the company greatly
relies on financing operations through barrowing. BioCryst Pharmaceuticals has a current ratio of 5.09, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about BioCryst Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. BioCryst Pharmaceuticals (BCRX) is traded on NASDAQ Exchange in USA. It is located in 4505 Emperor Boulevard, Durham, NC, United States, 27703 and employs 536 people. BioCryst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.
Management Performance
BioCryst Pharmaceuticals Leadership Team
Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alane Barnes, VP, General Counsel and Corporate Secretary | |
| Yarlagadda Babu, Sr. VP of Drug Discovery | |
| Elliott Berger, VP Affairs | |
| William MBBS, Chief Officer | |
| Stephanie Angelini, Chief Officer | |
| Michael Jones, Executive Officer | |
| Clayton Fletcher, Chief Officer | |
| Jon Stonehouse, CEO and President and Executive Director | |
| Philip George, Chief Officer | |
| Salisa Hauptmann, Chief Officer | |
| John Bluth, IR Contact Officer | |
| Charles Gayer, Senior Officer | |
| Jinky Rosselli, Chief Officer | |
| Anthony Doyle, Senior CFO | |
| MD FAAP, Chief Officer | |
BioCryst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to
measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.